Ning Z. Wu
Experienced in Hypogonadism Primary Partial Alopecia

Dr. Ning Z. Wu

Urology
22285 N Pepper Rd, 
Lake Barrington, IL 
On Staff At
Offers Telehealth
Experienced in Hypogonadism Primary Partial Alopecia
22285 N Pepper Rd, 
Lake Barrington, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ning Wu is an Urologist in Lake Barrington, Illinois. Dr. Wu is rated as an Experienced provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are UPJ Obstruction, Perirenal Abscess, Boils, Ureteroscopy, and Prostatectomy.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Duke University School Of Medicine, MD
Residency
Duke University Medical Center, General Surgery
Specialties
Urology
Licenses
Urology in IL
Board Certifications
American Board Of Urology
Hospital Affiliations
St Alexius Medical Center
Northwestern Medicine Mchenry
Advocate Sherman Hospital
Northwestern Medicine Central Dupage Hospital
Advocate Good Shepherd Hospital
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sutter Health
  • HMO
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 19 Less Insurance Carriers -

Locations

Comprehensive Urologic Care, SC
22285 N Pepper Rd, Lake Barrington, IL 60010
Other Locations
Comprehensive Urologic Care
1585 N Barrington Rd, Ste 206, Hoffman Estates, IL 60169
Comprehensive Urologic Care
1600 N Randall Rd, Ste 201, Elgin, IL 60123

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study)
A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study)
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2019
View 5 Less Clinical Trials

5 Total Publications

Task Modulation of Resting-State Functional Gradient Stability in Lifelong Premature Ejaculation: An FMRI Study.
Task Modulation of Resting-State Functional Gradient Stability in Lifelong Premature Ejaculation: An FMRI Study.
Journal: eNeuro
Published: February 09, 2025
Similar Doctors
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Gregory J. Andros
Urology
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Gregory J. Andros
Urology

Uropartners LLC

1401 Lakewood Dr, Unit 3, 
Morris, IL 
 (58.7 miles away)
815-409-4930
Languages Spoken:
English, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Andros is an Urologist in Morris, Illinois. Dr. Andros is rated as a Distinguished provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Enlarged Prostate (BPH), Male Pseudohermaphroditism with Gynecomastia, Eunuchoidism Familial Hypogonadotropic, Ureteroscopy, and Prostatectomy. Dr. Andros is currently accepting new patients.

Nelson E. Bennett
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Nelson E. Bennett
Urology
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Nelson E. Bennett
Urology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (35.4 miles away)
312-695-8146
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nelson Bennett is an Urologist in Chicago, Illinois. Dr. Bennett has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Testicular Failure, Peyronie Disease, Erectile Dysfunction (ED), Vasectomy, and Prostatectomy.

Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Peter Tek
Urology
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Peter Tek
Urology

Uropartners LLC

801 S Milwaukee Ave, 
Libertyville, IL 
 (12.3 miles away)
847-362-2900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Tek is an Urologist in Libertyville, Illinois. Dr. Tek is rated as a Distinguished provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Obstructive Uropathy, Enlarged Prostate (BPH), UPJ Obstruction, Ureteroscopy, and Gastrostomy. Dr. Tek is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wu's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile